Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05154474
Other study ID # WP-2021-03
Secondary ID 2021-A01670-41
Status Not yet recruiting
Phase
First received
Last updated
Start date June 2022
Est. completion date August 2024

Study information

Verified date November 2021
Source Weprom
Contact Magali BALAVOINE
Phone +33(0)241682940
Email m.balavoine@ilcgroupe.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people. Initially described for elderly patients, it is also presented as a negative prognostic factor in overall survival in oncology in certain locations (lung, ENT pathways, colon, pancreas) and more controversially for hemopathies. Its screening by measurement of skeletal muscle mass by CT scan and / or PET scan against L3 and by physical functional tests is not routinely integrated despite international recommendations. Sarcopenia is one of the characteristics of patient fragility that can induce more complications, lengthen the average length of hospital stay and reduce overall survival. The PRONOPALL score, a predictor score for survival validated by a previous study, will be correlated with the presence (or absence) of sarcopenia at inclusion for patients with a solid tumor (breast, ovary, prostate cancer , kidney, lungs, pancreas, colorectal). A prospective study on 38 patients with metastatic cancer was carried out at the Victor Hugo clinic in Le Mans between 01/JUN/21 and 31/AUG/21 (SPACE, ClinicalTrials.gov number, NCT04714203): 25 patients were analyzable on the CT and PRONOPALL score data with a prevalence of sarcopenia of 60% and median overall survival of 14 months (unpublished data), clinical performance and muscle strength tests were not carried out (as in the publications cited above). A prospective study for the detection of sarcopenia is indicated by extending to blood diseases with the integration of clinical tests included in the initial APA (Adapted physical activity) assessment recommended for diagnosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date August 2024
Est. primary completion date February 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient aged 18 years or older 2. Patient with solid cancer diagnosed with metastatic disease,or hematological disease requiring treatment (myeloma, lymphoma, high-risk myelodysplasia, acute or chronic myeloid leukemia, acute and chronic lymphoid leukemia) 3. Patient naive of cancer treatment 4. Pathology including performing a CT scan with cuts of the lumbar spine in standard care 5. Patient enrolled in social security 6. Patient has given his written consent ahead of any specific protocol procedure. Exclusion Criteria: 1. Minor patient 2. Metastatic neurological impairment 3. Patient deprived of their liberty, under guardianship or trusteeship 4. Patient with dementia, mental disorders or psychological pathology which could compromise patient informed consent and/or the observance of the study protocol 5. Patient cannot submit to the protocol for psychological, social, familial or geographical reasons 6. Patient is pregnant 7. History of cancer treated (excluding surgery alone for tumors in situ) within 5 years of inclusion

Study Design


Related Conditions & MeSH terms

  • Breast Neoplasms
  • Cancer Colon
  • Cancer Ovaries
  • Cancer Pancreas
  • Cancer Prostate
  • Cancer, Breast
  • Cancer, Kidney
  • Cancer, Lung
  • Cancer, Rectum
  • Hematologic Neoplasms
  • Kidney Neoplasms
  • Leukemia
  • Leukemia, Lymphocytic, Acute
  • Leukemia, Lymphocytic, Chronic
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid
  • Leukemia, Myeloid, Acute
  • Leukemia,Myeloid, Chronic
  • Lung Neoplasms
  • Metastatic Cancer
  • Myelodysplasia
  • Myeloma
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplasms, Second Primary
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Rectal Neoplasms
  • Sarcopenia

Intervention

Other:
Standard
Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires

Locations

Country Name City State
France Clinique Victor Hugo/Centre Jean Bernard Le Mans
France Clinique privé du Confluent Nantes

Sponsors (1)

Lead Sponsor Collaborator
Weprom

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of patients with sarcopenia diagnosed with metastatic cancer. Sarcopenia is defined for those under 60 years of age by LMSI<43.1 cm²/m² for men and <32.7 cm²/m² for women, and for patients over 60 years of age by <38.6 cm²/m² for men and <30.7 cm²/m² for women.. At inclusion
Secondary Overall Survival Calculated from the date of inclusion to the date of death due to any cause or the date last known to be alive if patient is censored. 18 months
Secondary Event Free survival Calculated from the date of start of treatment to the date of first event (progression, death, infectious complications, thrombosis, side effects of treatments of grade 2 or higher) 18 months
Secondary Progression Free survival Calculated from the date of start of treatment to the date of first progression of disease based on Investigator assessment or the date of death or censored at the date of the last valid tumor assessment before start of a new therapy for patients who are still alive and without progression 18 months
Secondary Unanticipated hospitalization rate Calculated from the date of start of treatment for all unplanned hospitalizations for side effects of treatments of grade 2 or higher, infectious complications, thrombosis, relapse or progression 18 months
Secondary Statistical relationship between sarcopenia and the PRONOPALL score For the cancer subtypes concerned (breast, colon, rectum, lungs, ovaries, prostate, kidney, pancreas) 18 months
Secondary Rate of undernourished patients Calculated according to WHO classification 18 months
Secondary Rate of patients with sarcopenia at diagnosis across the inclusive population Calculated from the number of patients who were screened for sarcopenia at diagnosis in the active file of patients meeting the inclusion criteria in all participating centers 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT05981170 - Rurality Adapted Physical Activity Sport Health
Not yet recruiting NCT03058809 - Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A